Myriad Genetic Laboratories is excited to announce the addition of our new riskScore breast cancer risk-prediction tool to the Myriad myRisk Hereditary Cancer test
The riskScore precision medicine tool is clinically validated to predict a woman’s risk of developing breast cancer using clinical risk factors and genetic-markers. It provides women with their remaining lifetime and 5-year risk for developing breast cancer.
riskScore analyzes over 80 well-studied genetic markers and combined with the Tyrer-Cuzick model estimates a woman’s risk for developing breast cancer. The genetic markers were recently validated in a set of over 17,000 patients in a study presented by Hughes, et al. at the American Society of Clinical Oncology (ASCO) Annual Meeting in June. An updated analysis will be presented at the National Society of Genetic Counselors (NSGC) Annual Education Conference this coming September. Additional studies are underway, with presentations and publications planned throughout the year.